cancer
xenograft
model
tumor
associ
antigen
highli
express
human
lung
cancer
cell
line
tumor
specimen
compar
normal
lung
tissu
deriv
peptid
strongli
inhibit
tumor
growth
cancer
metastasi
prolong
surviv
time
transgen
mice
immun
formul
thelper
th
peptid
synthet
cpg
odn
adjuv
montanid
adopt
transfer
peptideinduc
ctl
cell
transgen
mice
human
tumor
xenograft
scid
mice
significantli
inhibit
tumor
growth
furthermor
combin
ctlpeptid
immunotherapi
gemcitabin
addit
improv
therapeut
effect
preclin
evalu
model
provid
use
platform
develop
effici
immunotherapeut
drug
treat
lung
cancer
demonstr
promis
strategi
benefit
antitumor
immun
respons
worthi
develop
clinic
trial
lung
cancer
one
lead
caus
malignancyrel
death
frequenc
highli
metastat
potenti
current
immunotherapi
lung
cancer
consid
promis
treatment
capabl
induc
system
tumorspecif
immun
respons
without
provok
seriou
side
effect
critic
factor
immunotherapi
choos
potenti
cancer
specif
antigen
target
without
affect
normal
tissu
tumorassoci
antigen
tumorspecif
antigen
distant
member
superfamili
often
overexpress
human
lung
breast
colon
cancer
tissu
normal
tissu
antibodybas
immunotherapi
membran
protein
use
treat
breast
cancer
clinic
studi
therapeut
effect
limit
sever
strategi
use
improv
immunotherapi
cancer
treatment
induct
cytotox
tcell
ctl
respons
lung
cancer
antigen
util
synthet
peptid
ctl
epitopesbas
vaccin
safe
easi
manufactur
clinic
use
recent
multipeptid
vaccin
design
induc
ctl
five
tumorassoci
antigen
taa
frequent
overexpress
nsclc
ie
carconoembryon
antigen
cea
melanoma
antigen
mage
provid
clinic
efficaci
metastat
nsclc
although
immunotherapi
cancer
vaccin
induc
ctl
nsclc
treatment
reveal
promis
effect
lack
proven
clinic
benefit
continu
block
develop
immunotherapi
develop
conveni
predict
model
evalu
ctl
activ
clinic
trial
critic
essenti
increas
success
rate
immunotherapi
studi
gener
transgen
mous
model
human
tumor
xenograft
scid
mice
model
investig
preclin
therapeut
effect
immunotherapi
human
tumor
via
adopt
transfer
restrict
ctl
recogn
human
tumor
antigen
tumor
specif
antigen
correl
cancer
metastasi
ctl
peptid
investig
elicit
tumor
specif
ctl
respons
addit
therapeut
effect
gemcitabin
preclin
trial
determin
whether
protein
overexpress
lung
cancer
cell
tumor
specif
antigen
treatment
lung
cancer
cell
line
primari
lung
tumor
tissu
nsclc
patient
stain
monoclon
antibodi
use
flow
cytometri
high
level
protein
detect
lung
cancer
cell
line
except
figur
compar
two
cell
line
origin
cell
popul
found
higher
express
cell
high
metastat
abil
compar
parent
cell
low
metastat
abil
figur
consist
previou
report
express
tumor
cell
associ
cancer
metastat
abil
addit
detect
primari
cultur
lung
cancer
cell
lung
cancer
patient
pleural
effus
figur
high
express
maintain
human
tumor
xenograft
scid
mice
figur
assess
clinic
relev
protein
express
lung
cancer
patient
perform
ihc
stain
lung
cancer
tissu
array
contain
tumor
adjac
normal
tissu
asian
patient
figur
comparison
set
score
posit
found
posit
stain
lung
cancer
tissu
normal
lung
tissu
figur
notabl
normal
lung
tissu
neg
maxim
score
posit
stain
normal
lung
tissu
detect
pair
tumor
posit
stain
figur
express
high
lung
cancer
tissu
remain
low
match
adjac
normal
lung
tissu
p
figur
furthermor
assess
diagnost
accuraci
perform
receiv
oper
characterist
roc
curv
analysi
use
medicin
determin
cutoff
valu
ihc
result
tissu
array
area
curv
auc
rang
random
chanc
predict
abil
perfect
discriminationaccuraci
roc
curv
analysi
area
curv
auc
sensit
specif
figur
indic
express
inde
abund
lung
cancer
tissu
immun
ctl
epitop
suppress
tumor
growth
transgen
mice
previou
studi
identifi
specif
ctl
epitop
call
peptid
could
induc
immun
specif
cytotox
ctl
immun
formul
incomplet
freund
adjuv
ifa
univers
th
epitop
pandr
peptid
breast
tumor
improv
immunestimulatori
activ
ctl
epitop
formul
peptid
adjuv
isa
see
materi
method
boost
host
immun
splenocyt
th
immun
tg
mice
restimul
cell
express
cell
express
alon
cell
vitro
found
higher
frequenc
cell
cytolyt
cell
cultur
cell
compar
cultur
cell
indic
cytolyt
cell
specif
ctl
peptid
immun
mice
activ
specif
recogn
cancer
cell
express
cell
without
express
support
function
immun
figur
immun
epitop
could
induc
ex
vivo
ctl
activ
presenc
investig
function
immun
vivo
tumor
develop
inocul
cancer
cell
transgen
mice
peptid
immun
growth
tumor
significantli
suppress
compar
tumor
figur
result
indic
peptid
immun
induc
ctl
respons
provid
therapeut
activ
coexpress
cancer
cell
improv
immun
peptid
ligand
cpg
adjuv
includ
peptid
montanid
transgen
mice
splenocyt
harvest
final
immun
cell
activ
analyz
use
secret
elispot
assay
formul
cpg
combin
montanid
peptid
th
peptid
ligand
cpg
induc
substanti
secret
compar
vs
figur
comparison
efficaci
adjuv
show
induc
strongest
secret
compar
addit
isa
provid
greater
adjuv
efficaci
cpg
supplementari
figur
isa
formul
induc
cell
activ
specif
peptid
measur
cell
surfac
flow
cytometri
use
mous
antibodi
green
line
isotyp
control
antibodi
shade
probe
goat
antimous
fitcconjug
antibodi
lung
cancer
cell
line
b
express
primari
cultur
lung
cancer
cell
pleural
effus
detect
flow
cytometri
panel
establish
two
individu
lung
cancer
patient
c
express
stain
xenograft
tumor
scid
mice
subcutan
inject
primari
cultur
lung
cancer
cell
ihc
stain
stage
iii
lung
cancer
patient
cancer
adjac
normal
pneumon
lung
tissu
enlarg
imag
shown
origin
ihc
stain
e
ihc
analysi
lung
cancer
tissu
array
score
stain
intens
neg
weak
moder
strong
histologist
posit
taken
score
greater
neg
indic
score
f
analysi
ihc
score
tumor
adjac
normal
tissu
g
roc
curv
analysi
predict
express
lung
tumor
tissu
ihc
result
lung
cancer
tissu
array
auc
sensit
specif
ex
vivo
figur
consist
cpg
induc
activ
cytotox
cell
stimul
cell
figur
determin
whether
ctl
respons
elicit
peptid
inhibit
cancer
metastas
tg
mice
cell
inject
intraven
develop
tumor
metastat
anim
model
metastat
tumor
lung
observ
immun
mice
day
tumor
inocul
wherea
lung
tumor
nodul
detect
group
figur
moreov
surviv
significantli
prolong
immun
mice
moder
enhanc
immun
mice
compar
control
mice
figur
detect
effect
peptid
specif
immun
suppress
metastasi
melanoma
cell
cell
express
intraven
inject
immun
transgen
mice
figur
gross
examin
whole
lung
specimen
demonstr
tumor
metastasi
lung
dramat
suppress
immun
mice
bear
tumor
compar
cell
group
protect
mice
revers
mice
indic
immun
induc
specif
immun
reduc
metastasi
thu
result
suggest
isa
could
induc
strong
specif
ctl
respons
cancer
metastas
tg
mice
determin
whether
induct
specif
ctl
respons
peptid
could
inhibit
transgen
mice
immun
sc
twice
peptid
formul
th
epitop
peptid
isa
isa
alon
final
immun
splenocyt
harvest
mice
cocultur
cell
hr
percentag
cell
detect
flow
cytometri
error
bar
sd
three
independ
experi
p
p
b
day
final
immun
pb
peptid
transgen
mice
cancer
cell
cell
per
mous
inject
subcutan
tumor
growth
monitor
group
contain
mice
error
bar
sem
p
figur
improv
immun
transgen
mice
prolong
anim
surviv
time
prevent
lung
metastas
transgen
mice
subcutan
immun
twice
peptid
th
epitop
peptid
cpgodn
isa
antitumor
effect
monitor
splenocyt
harvest
incub
peptid
irrelev
peptid
secret
cell
detect
elispot
assay
error
bar
sd
p
b
splenocyt
harvest
peptid
immun
mice
stimul
peptidesfor
hr
presenc
peconjug
stimul
fitcconjug
antibodi
use
detect
cell
percentag
cell
individu
immun
group
determin
flow
cytometri
c
irradi
cell
use
stimul
splenocyt
hr
percentag
cell
determin
flow
cytometri
panel
b
describ
peptid
immun
cell
cell
inocul
iv
rout
lung
tissu
group
collect
tumor
nodul
detect
day
tumor
implant
e
mice
surviv
time
monitor
analyz
p
p
f
melanoma
cell
cell
express
intraven
inject
immun
transgen
mice
whole
lung
examin
growth
human
lung
cancer
cell
human
tumor
xenograft
anim
model
establish
assess
therapeut
effect
ctl
peptid
elicit
immun
respons
identifi
hla
type
human
lung
cancer
cell
line
cell
hla
use
establish
lung
cancer
anim
model
treatment
immun
isa
twice
transgen
mice
ctl
destroy
lung
cancer
cell
specif
cytotox
inhibit
either
monoclon
antibodi
vitro
figur
evalu
therapeut
efficaci
peptideinduc
ctl
respons
human
tumor
xenograft
anim
model
purifi
cell
peptid
immun
tg
mice
intraven
transfer
scid
mice
bear
tumor
day
tumor
progress
mice
receiv
adopt
transfer
cell
thcpgisa
immun
mice
reduc
significantli
compar
control
group
figur
indic
antitumor
activ
peptid
immun
ctl
cell
human
lung
cancer
cell
vivo
myeloid
deriv
suppressor
cell
mdsc
repres
one
critic
barrier
effect
immun
respons
detect
elimin
cancer
cell
gemcitabin
gem
pyrimidin
antimetabolit
clinic
use
cancer
treatment
report
reduc
frequenc
mdsc
found
percentag
mdsc
increas
scid
mice
bear
tumor
decreas
gem
treatment
indic
role
gem
modul
mdsc
figur
determin
whether
combin
treatment
gem
ctl
peptid
immun
enhanc
anticanc
activ
ctl
deriv
peptideimmun
transgen
mice
adopt
transfer
scid
mice
bear
tumor
without
gem
treatment
although
treatment
gem
adopt
transfer
peptid
vaccin
cell
provid
signific
antitumor
effect
combin
two
treatment
reduc
tumor
size
dramat
effect
prolong
mice
surviv
figur
comparison
median
surviv
time
show
cell
group
longest
surviv
day
better
day
gemcontrol
day
gem
day
control
day
pb
day
group
investig
whether
mdsc
elimin
peptid
deriv
ctl
critic
addit
effect
combin
antitumor
therapi
tumorinfiltr
cell
popul
analyz
percentag
mdsc
significantli
decreas
gem
gem
combin
peptid
vaccin
cell
group
figur
larg
number
tumorinfiltr
cell
detect
mice
receiv
control
cell
vaccin
cell
gem
combin
peptid
vaccin
cell
group
figur
howev
percentag
tetramerbind
cell
indic
specif
deriv
ctl
greatli
increas
mice
treat
gem
peptid
vaccin
cell
compar
group
figur
even
though
two
group
similar
cell
percentag
figur
like
reduct
mdsc
gemcitabin
preserv
specif
deriv
cell
tumor
result
suggest
improv
therapeut
applic
gem
adopt
transfer
peptid
vaccin
cell
furthermor
evalu
vaccin
could
suppress
establish
tumor
treat
tumor
day
cancer
cell
inocul
gem
adopt
transfer
peptid
vaccin
cell
suppress
tumor
growth
combin
treatment
show
addit
antitumor
activ
figur
although
consid
target
antibodybas
immunotherapi
breast
lung
cancer
past
decad
therapeut
effect
antibodybas
immunotherapi
limit
human
altern
cellbas
immunotherapi
may
feasibl
approach
cancer
treatment
recent
identifi
ctl
epitop
stimul
ctl
activ
kill
breast
cancer
cell
vitro
studi
extend
cellbas
immunotherapi
lung
cancer
treatment
protein
previous
detect
antibodi
nsclc
tissu
express
frequenc
protein
lung
cancer
less
report
asian
patient
report
found
highli
express
lung
cancer
tissu
asian
patient
suggest
could
tumor
antigen
ctl
epitop
peptid
induc
antitumor
effect
lung
cancer
transgen
mice
adopt
transfer
cell
peptid
immun
mice
scid
mice
inhibit
tumor
growth
human
lung
cancer
xenograft
importantli
addit
improv
therapeut
effect
cellbas
immunotherapi
gemcitabin
chemotherapi
observ
human
cancer
xenograft
model
result
demonstr
peptid
immun
elicit
ctl
respons
feasibl
lung
cancer
treatment
immunotherapi
induc
cytotox
lymphocyt
ctl
activ
import
inhibit
human
tumor
growth
promis
strategi
defici
good
evalu
system
preclin
therapeut
studi
major
challeng
cellbas
immunotherapi
assess
due
human
hla
restrict
therapeut
ctl
peptid
develop
conveni
model
evalu
ctl
activ
clinic
trial
transgen
mice
immun
differ
formul
adjuv
use
human
clinic
trial
safer
incomplet
adjuv
ifa
found
formul
peptid
th
epitop
tlr
agonist
cpg
isa
provid
stronger
antitumor
effect
formul
result
demonstr
figur
peptid
immun
induc
specif
cytotox
lymphocyterespons
transgen
mice
effector
cell
splenocyt
immun
transgen
mice
stimul
peptid
subject
standard
crreleas
assay
cell
target
antibodi
migg
isotyp
control
incub
effector
cell
hour
ctl
assay
done
mice
per
group
observ
effectortarget
et
ratio
p
b
treatment
schedul
shown
top
cell
subcutan
inocul
scid
mice
purifi
cell
peptid
immun
tg
mice
adopt
transfer
iv
rout
individu
scid
mous
bear
tumor
day
tumor
size
monitor
day
group
contain
mice
error
bar
sem
p
emuls
type
adjuv
isa
may
prolong
cpg
releas
enhanc
ctl
respons
find
similar
previou
report
emuls
type
adjuv
pelc
could
enhanc
ctl
respons
antitumor
effect
presenc
cpg
odn
thu
combin
emuls
type
adjuv
agonist
potent
formul
peptidebas
therapeut
vaccin
cancer
therapi
prove
adopt
transfer
ctl
tg
mice
could
inhibit
cell
growth
scid
mice
support
notion
peptid
could
effect
human
howev
still
room
improv
antitumor
effect
peptid
immun
tumorinfiltr
immunosuppress
cell
impair
ctl
function
tumor
microenviron
major
barrier
cancer
therapi
overcom
immunosuppress
microenviron
sever
approach
aim
deplet
immunosuppress
cell
includ
antibodi
delet
chemotherapeut
drug
tlr
ligand
modul
select
gemcitabin
combin
therapi
gemcitabin
report
inhibit
treg
mdsc
tumor
microenviron
enhanc
antitumor
immun
confirm
number
mdsc
reduc
human
tumorbear
scid
mice
treat
gemcitabin
gemcitabin
combin
cell
adopt
transfer
immun
tg
mice
significantli
suppress
growth
human
tumor
scid
mice
observ
impli
combin
chemodrug
cellbas
immunotherapi
might
benefit
cancer
patient
provid
direct
evid
cell
abl
kill
human
lung
cancer
express
highlevel
vitro
vivo
addit
show
peptid
formul
isathcpg
elicit
strong
antitumor
immun
achiev
maximum
antitumor
abil
select
suitabl
adjuv
import
futur
th
epitop
could
conjug
ctl
epitop
simplifi
peptidesynthet
process
furthermor
multipl
ctl
epitop
differ
function
tumorassoci
antigen
could
ad
boost
ctl
activ
recent
found
critic
endotheli
cell
function
tumor
angiogenesi
could
vascular
therapeut
target
cancer
therapi
anoth
famili
protein
overexpress
hepatocellular
carcinoma
colon
cancer
monoclon
antibodi
could
inhibit
colon
cancer
growth
mous
model
studi
demonstr
famili
protein
may
good
target
antibodybas
cancer
immunotherapi
therefor
current
studi
provid
promis
strategi
facilit
success
cancer
therapi
cancer
express
famili
protein
protein
cell
detect
flow
cytometri
use
mous
monoclon
antibodi
rabbit
antihuman
antibodi
sigma
use
detect
lung
cancer
tissu
immunohistochem
ihc
stain
horseradish
peroxidaseconjug
avidin
biotin
complex
abc
vectastain
elit
abc
kit
vector
laboratori
burlingam
ca
aec
chromogen
vector
laboratori
section
counterstain
hematoxylin
mount
asian
lung
cancer
tissu
array
purchas
us
biomax
rockvil
md
stain
evalu
experienc
histologist
human
lung
adenocarcinoma
cell
line
low
invas
high
invas
establish
lung
cancer
origin
primari
cultur
cell
line
establish
pleural
effus
two
individu
adenocarcinoma
lung
cancer
patient
written
inform
consent
patient
lung
cancer
cell
line
obtain
bioresourc
collect
research
center
hsinchu
taiwan
cell
stabli
express
cell
cell
cell
stabli
express
cell
cultur
medium
supplement
fetal
bovin
serum
fb
transgen
mice
kindli
provid
professor
showli
chen
nation
taiwan
univers
taiwan
anim
experi
perform
specifi
pathogenfre
spf
condit
protocol
approv
anim
committe
nation
health
research
institut
nhri
peptid
llmllpafv
protein
identifi
specif
ctl
epitop
previou
studi
irrelev
peptid
lyltqdlfl
spike
protein
sar
cov
includ
immun
peptid
puriti
synthes
peptid
synthesi
core
facil
nation
health
research
institut
nhri
taiwan
peptid
dissolv
dmso
mg
ml
stock
solut
store
analyz
hplc
mass
spectrometri
verifi
puriti
peptid
immun
perform
previous
describ
brief
mg
ctl
peptid
mg
th
epitop
peptid
padr
akfvaawtlkaaa
ml
pb
mix
ml
montanid
isa
isa
seppic
compani
mixtur
inject
sc
tg
mice
twice
interv
splenocyt
collect
day
second
inject
elispot
assay
cell
detect
elispot
assay
perform
previous
describ
brief
spleen
cell
ml
indic
peptid
ad
pvdfmembran
plate
coat
antibodi
spot
develop
use
carbazol
aec
sigma
solut
reaction
stop
minut
run
plate
tap
water
spot
count
use
elispot
reader
cellular
technolog
ltd
shaker
height
oh
tg
mice
inject
sc
twice
interv
formul
th
cpg
cpg
purchas
genedirex
consist
sequenc
phosphorothio
backbon
cell
harvest
mous
cell
dynabead
invitrogen
cell
inocul
sc
opposit
site
peptid
inject
seven
day
second
immun
tumor
size
measur
time
per
week
use
formula
tumor
volum
length
x
width
x
width
metastat
mous
model
melanoma
tg
mice
immun
procedur
cell
intraven
inject
day
post
final
immun
lung
tissu
collect
fix
formalin
detect
tumor
nodul
day
tumor
inocul
human
tumor
xenograft
model
human
lung
cancer
cell
subcutan
inject
scid
mice
biolasco
taiwan
gener
human
tumor
xenograft
anim
model
purifi
cell
peptideimmun
tg
mice
intraven
deliv
scid
mice
day
post
tumor
inocul
combin
therapi
day
inocul
gemcitabin
administ
ip
singl
dose
cancer
xenotranspl
mice
day
gemcitabin
administr
isol
cell
adopt
transfer
mice
cytotox
assay
describ
previou
report
tg
mice
inject
sc
twice
indic
peptid
emulsifi
isa
presenc
th
peptid
cpgodn
day
second
immun
splenocyt
harvest
suspend
cellml
medium
contain
indic
peptid
cell
cellml
peconjug
monoclon
antibodi
roundbottom
plate
hour
incub
brefeldin
monensin
ad
anoth
hour
plate
wash
pb
contain
fb
rat
antimous
fc
antibodi
ad
minut
follow
addit
fitcconjug
rat
antimous
antibodi
minut
cytotox
cell
analyz
flowcytomet
fac
calibur
bd
bioscienc
analyz
cell
cytotox
transgen
mice
subcutan
immun
twice
peptid
cpgodn
isa
day
final
immun
spleen
lymph
node
isol
stimul
peptid
ml
day
effector
cell
effector
cell
incub
mous
rat
mous
rat
igg
isotyp
control
antibodi
hour
cell
label
chromium
hour
target
cell
target
cell
well
incub
e
cell
ratio
final
volum
hour
supernat
harvest
cr
releas
measur
spontan
releas
measur
well
contain
target
cell
alon
maximum
cr
releas
target
cell
measur
ad
triton
specif
lysi
calcul
test
cr
releas
spontan
cr
maximum
cr
releas
spontan
cr
cell
surfac
marker
stain
flow
cytometri
perform
previous
describ
briefli
cell
suspens
tumorbear
mice
mechan
disrupt
fragment
hr
cell
adopt
transfer
cell
stain
peconjug
antibodi
quantifi
mdsc
fitcconjug
quantifi
cell
peconjug
tetram
detect
cell
cell
popul
determin
via
flow
cytometri
facscalibur
bd
bioscienc
san
jose
ca
usa
data
acquir
use
facscalibur
devic
plot
use
fc
express
version
softwar
research
edit
de
novo
statist
signific
differ
mean
valu
experiment
group
determin
use
one
way
analysi
varianc
anova
differ
consid
statist
signific
p
valu
